Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

A gene therapy company creating precise treatments for rare genetic diseases.

Rare DiseaseGenetics & Genomics

Technology Platform

A proprietary platform combining novel viral vectors and gene editing technologies designed for precise, durable, and safe genomic correction in target tissues.

Funding History

1
Total raised:$50M
Venture$50M

Opportunities

Potential for breakthrough therapy designations and premium pricing in niche rare disease markets with no existing treatments.

Risk Factors

High clinical development risks inherent to novel gene therapies, including safety concerns and challenges in manufacturing and delivery.

Competitive Landscape

Competes with larger gene therapy firms like BioMarin and Sarepta, as well as numerous biotech startups, in a crowded but high-value rare disease space.